HUP9701695A2 - {2-[1,1-Dioxi-3(2H)-oxo-1,2-benzizotiazol-2-il]-etil}-5-(etoxi-karbonil)-2,4,6-trimetil-1,2-dihidro-piridin-3-karboxilát alkalmazása atherosclerosis elleni gyógyszerkészítmény előállítására - Google Patents

{2-[1,1-Dioxi-3(2H)-oxo-1,2-benzizotiazol-2-il]-etil}-5-(etoxi-karbonil)-2,4,6-trimetil-1,2-dihidro-piridin-3-karboxilát alkalmazása atherosclerosis elleni gyógyszerkészítmény előállítására

Info

Publication number
HUP9701695A2
HUP9701695A2 HU9701695A HUP9701695A HUP9701695A2 HU P9701695 A2 HUP9701695 A2 HU P9701695A2 HU 9701695 A HU9701695 A HU 9701695A HU P9701695 A HUP9701695 A HU P9701695A HU P9701695 A2 HUP9701695 A2 HU P9701695A2
Authority
HU
Hungary
Prior art keywords
ethoxycarbonyl
carboxylate
trimethyl
ethyl
benzisothiazolyl
Prior art date
Application number
HU9701695A
Other languages
English (en)
Inventor
Francisco Javier Cillero Corral
Miguel Fau De Casajuana Munoz
Pilar Ortega Navarrete
Jaime Priego Fernandez Del Campo
Luis Santos Gil
Carlos Sunkel Letelier
Original Assignee
Laboratorios Alter, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Alter, S.A. filed Critical Laboratorios Alter, S.A.
Publication of HUP9701695A2 publication Critical patent/HUP9701695A2/hu
Publication of HUP9701695A3 publication Critical patent/HUP9701695A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány a {2-[1,1-diőxi-3(2H)-őxő-1,2-benzizőtiazől-2-il]-etil}-5-(etőxi-karbőnil)-2,4,6-trimetil-1,2-dihidrő-piridin-3-karbőxilátalkalmazására vőnatkőzik atherősclerősisős és/vagy érszűkületbenszenvedő betegek kezelésére használható gyógyszerek előállítására,akiknél kőmőly veszélye van a megbetegedett erek elzáródásának. A {2-[1,1-diőxi-3(2H)-őxő-1,2-benzizőtiazől-2-il]-etil}-5-(etőxi-karbőnil)-2,4,6-trimetil-1,2-dihidrő-piridin-3-karbőxilátőt őrálisan vagyparenterálisan adagőlják önmagában, vagy egyéb gyógyszerekkelkőmbinációban atherősclerőtikűs betegségben szenvedő betegeknek, azatherőmás sérülés csökkentésére és az éredényekben a szűkületújraképződésének megelőzésére. ŕ
HU9701695A 1995-08-25 1996-08-20 Use of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl for producing pharmaceuticals against atherosclerosis HUP9701695A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95500122A EP0771560A1 (en) 1995-08-25 1995-08-25 Use of 2- N-(1,2-benzoisothiazolyl-3(2H)one-1,1-dioxide ethyl 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropiridine-3-carboxylate in the treatment of vascular disorders

Publications (2)

Publication Number Publication Date
HUP9701695A2 true HUP9701695A2 (hu) 1998-03-30
HUP9701695A3 HUP9701695A3 (en) 1999-10-28

Family

ID=8221657

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9701695A HUP9701695A3 (en) 1995-08-25 1996-08-20 Use of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl for producing pharmaceuticals against atherosclerosis

Country Status (12)

Country Link
EP (1) EP0771560A1 (hu)
JP (1) JPH10508879A (hu)
KR (1) KR970706817A (hu)
AU (1) AU6931496A (hu)
BR (1) BR9606691A (hu)
CA (1) CA2203624A1 (hu)
EA (1) EA199700053A1 (hu)
HU (1) HUP9701695A3 (hu)
IL (1) IL120718A0 (hu)
MX (1) MX9703032A (hu)
WO (1) WO1997007801A1 (hu)
ZA (1) ZA967223B (hu)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3617976A1 (de) * 1986-05-28 1988-01-14 Alter Sa 1,4-dihydropyridin, verfahren zu dessen herstellung und dessen verwendung in antithrombotischen medikamenten

Also Published As

Publication number Publication date
EA199700053A1 (ru) 1997-12-30
AU6931496A (en) 1997-03-19
CA2203624A1 (en) 1997-03-06
MX9703032A (es) 1997-12-31
KR970706817A (ko) 1997-12-01
JPH10508879A (ja) 1998-09-02
EP0771560A1 (en) 1997-05-07
BR9606691A (pt) 2000-05-09
IL120718A0 (en) 1997-08-14
HUP9701695A3 (en) 1999-10-28
ZA967223B (en) 1997-03-03
WO1997007801A1 (es) 1997-03-06

Similar Documents

Publication Publication Date Title
HUP9902105A2 (hu) Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
TR200001982T2 (tr) Farmasötik vurulu salınımlı oral dozaj şekli.
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DE68911891D1 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
HUP0402304A2 (hu) Deutériummal helyettesített dihidrofuranonszármazékok és azokat tartalmazó gyógyszerkészítmények
DE69230037D1 (de) Kontinuierliche zellinie sowie impfstoff gegen geflügelinfektion mit kokkidien
HUP9701777A2 (hu) Raloxifene alkalmazása mellrák megelőzésére alkalmas gyógyszerkészítmények előállítására
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
ATE94401T1 (de) Physiologisch wirkende substanzen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen davon.
ATE360428T1 (de) Analgetisches arzneimittel
NO20053032L (no) Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon.
HUP9701695A2 (hu) {2-[1,1-Dioxi-3(2H)-oxo-1,2-benzizotiazol-2-il]-etil}-5-(etoxi-karbonil)-2,4,6-trimetil-1,2-dihidro-piridin-3-karboxilát alkalmazása atherosclerosis elleni gyógyszerkészítmény előállítására
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
BR9813641A (pt) "preparados transmucosais de levosimendan"
RU99112945A (ru) Новое применение креатина
HUP0401798A2 (hu) Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására
EP0305277A3 (fr) Application de l'amino-2 trifluoro-méthoxy-6 benzothiazole pour obtenir un médicament destiné au traitement des troubles du sommeil et de la dépression
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
Samuel et al. Amiodarone and hair loss.
HUP9701284A2 (hu) 2,3-Benzodiazepin-származékok felhasználása az endogén opioid rendszerrel összefüggő betegségek és állapotok kezelésére, és megelőzésére alkalmas gyógyászati készítmények előállítására
EP0880967A3 (de) Nephroprotektive Arzneimittel
DE3866300D1 (de) Erzeugnisse, enthaltend gallopamil und prazosin.
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
Cummings Oral manifestations of connective tissue disease